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Abstract
Background: To investigate the biological radiation dose-response for patients of limited-stage small-cell lung
cancer (LS-SCLC) treated with high radiation dose.
Methods: Two hundred and five patients of LS-SCLC treated with sequential chemotherapy and thoracic
radiotherapy with involved-field between 1997 and 2006 were reviewed retrospectively. Biologically effective dose
(BED) was calculated for dose homogenization and was corrected with the factor of overall radiation time. Patients
were divided into low BED group (n = 70) and high BED group (n = 135) with a cut-off of BED 57 Gy (equivalent
to 60 Gy in 30 fractions over 40 days). Outcomes of the two groups were compared.
Results: Median follow-up was 20.7 months for all analyzable patients and 50.8 months for surviving patients.
Considering all patients, median survival was 22.9 months (95% confidence interval, 20.6-25.2 months); 2- and
5-year survival rates were 47.2% and 22.3%, respectively. Patients in high BED group had a significantly better local
control (p = 0.024), progression-free survival (p = 0.006) and overall survival (p = 0.005), with a trend toward
improved distant-metastasis free survival (p = 0.196). Multivariable Cox regression demonstrated that age (p =
0.003), KPS (p = 0.009), weight loss (p = 0.023), and BED (p = 0.004) were significant predictors of overall survival.
Conclusions: Our data showed that a high BED was significantly associated with favourable outcomes in the
Chinese LS-SCLC population, indicating that a positive BED-response relationship still existed even in a relatively
high radiation dose range.
Background
Although concurrent thoracic radiotherapy (TRT) com-
bined with chemotherapy represents the standard of
care in the management of limited-stage small-cell lung
cancer (LS-SCLC), the optimal radiation schedule and
total dose for LS-SCLC remain topics of continuous
debate [1,2]. In the landmark study of Intergroup Trial
0096 [3], Turrisi et al. demonstrated that twice-daily
TRT of 45 Gy over 3 weeks yielded both superior local
control (LC) and overall survival (OS) rate compared to
once-daily TRT of 45 Gy over 5 weeks, strongly sugges-
tive of enhanced dose intensification may improve LC
which resulted in prolonged OS in LS-SCLC. Neverthe-
less, high frequency of local failure rate (36%) despite
bid TRT [3] has led to investigations of higher doses of
TRT. Higher dose up to 70 Gy of once-daily TRT for
LS-SCLC is feasible, as have been showed in several ret-
rospective and prospective small studies [4-7]. Also, the
regimen of 61.2 Gy concomitant boost TRT was investi-
gated in phase I and II studies by the Radiation Therapy
Oncology Group (RTOG) [8,9]. However, none of these
high dose regimens appeared to be superior to 45 Gy
over 3 weeks in terms of tumor control rate even
though tolerability were generally reported.
Multiple studies have confirmed that there is a radia-
tion dose-response for SCLC but the radiation dose
evaluated was often in the lower range of 25-50 Gy
[10-12]. Choi et al. reported a positive dose-response
relationship with a LC rate of 16%, 51%, 63%, and 78%
for a radiation dose of 30, 40, 50, and 57 Gy (range
50-72), respectively [5,11]. But there was no significant
difference in outcomes between patients treated with a
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group analysis.
As SCLC presents the biological characteristics of sen-
sitivity to treatment and early spread to distant sites, we
really do not know whether further increase of TRT
dose is necessary for LS-SCLC. Our concern is whether
a dose-response relationship still exists for improved LC
and OS in LS-SCLC when a certain threshold of TRT
intensity has been reached. Unfortunately, few studies
have been specifically addressed this critical issue for
LS-SCLC. In order to evaluate if there is a dose-
response relationship, the outcome of LS-SCLC patients
treated consecutively at our centre with combination of
chemotherapy and TRT with doses greater than 50 Gy
were reviewed. Since radiation dose confounds both
fractionation and overall radiation time (ORT), the bio-
l o g i c a l l ye f f e c t i v ed o s e( B E D )w i t hO R Tw i l lb eam o r e
appropriate representative of the biological effect than
the single physical dose. Thus we investigated the
underlying BED-response relationship for LS-SCLC in
this study.
Methods
Patients
Medical and RT records of all patients with LS-SCLC
between 1997 and 2006 were reviewed. Patients were
selected based on the initial diagnosis of LS-SCLC
where definitive TRT with doses equal or greater than
50 Gy was carried out as a part of their treatment for
this disease. All patients had histology confirmed SCLC
by bronchoscopic, transthoracic biopsy or sputum cytol-
ogy no less than twice. Pre-treatment staging procedures
consistently included clinical history, physical examina-
tion, biochemical test, computed tomography (CT) scan
of the thorax and abdomen, magnetic resonance ima-
ging or CT scan of the brain, and bone scan. Limited-
stage disease was defined as disease confined to one
hemithorax which can be safely encompassed within a
tolerable radiation field. Presence of an ipsilateral pleural
effusion was classified as limited-stage if cytology was
negative or if the effusion was small.
A total of 234 patients were identified as LS-SCLC in
the period, 29 were excluded because they had under-
gone surgery (n = 14) or had been treated to dose < 50
Gy (n = 15). For all 205 patients with definitive chemor-
adiotherapy, median age at diagnosis was 62 years
(range 35-83) and median KPS was 80 (range 60-100).
Treatment Decision
Treatment strategies were determined on the basis of
tumor status, patient’s performance and comorbidities at
the discretion of the treating oncologist, and referring to
the clinical practice guidelines formulated in our centre.
The majority of patients were given modified chemora-
diotherapy because of concerns of serious toxicity from
concurrent chemoradiotherapy and insufficient suppor-
tive treatment in developing country [13]. Generally, 2-4
cycles of induction chemotherapy were administered,
followed by initiation of TRT within 1 week after the
start of the last cycle of induction chemotherapy, and
then 2-4 cycles of adjuvant chemotherapy delivered
within a week at the end of TRT. Chemotherapy was a
combination of platinum and etoposide regimen, typi-
cally delivered every 3-4 weeks per cycle. After the com-
pletion of TRT and chemotherapy, patients with a
complete clinical/radiological response received prophy-
lactic cranial irradiation (PCI) with 25 Gy in 10 fractions
over 2 weeks. However, due to the poor treatment
adherence to preventive intervention, only 12% of the
patients undertook PCI in our study population.
Thoracic Radiotherapy
During the period, TRT was delivered with megavoltage
equipment (6-15 MV), and either two-dimensional or
three-dimensional techniques were allowed. The gross
target volume (GTV) was based on the restaging chest
CT obtained after the last induction chemotherapy,
including the primary tumor (post-chemotherapy) and all
clinical/radiological involved lymphatic regions with a
short-axis diameter ≥ 1 cm (pre- or post-chemotherapy).
Elective treatment of clinically uninvolved lymphatic
regions was not carried out. No specific clinical target
volume (CTV) was used in this population. A margin of
1.0-1.5 cm was placed to form planning target volume
(PTV) according the site and motion of the target (the
margin of 1.5 cm was commonly used in the most of
patients). Typically, patients with two-dimensional plan-
ning were treated with equally weighted AP-PA fields to
40-42 Gy, then boost by parallel opposed off cord oblique
fields to the prescribed dose. For patients with three-
dimensional planning, three to six coplanar photon fields
were used and the prescribed dose was corrected for lung
inhomogeneity. As for the dose fractionation scheme,
both once-daily and twice-daily fractions were used in
the period, which was chosen mainly depended on the
attending physician’s judgment and preference. For
patients with once-daily TRT, a total dose of 50-70 Gy
was administered at 1.8-2.5 Gy per fraction. For patients
with twice-daily TRT, a total dose of 56 Gy at 1.4 Gy per
fraction was delivered at intervals longer than 6 h, in 40
fractions over 4 weeks, which has been described pre-
viously [13].
Radiation Dose Homogenization
To enable comparison of the physical dose values with
different fractionation schemes, we calculated the BED
using the linear quadratic formula that included the
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accelerated proliferation during irradiation course [14].
BED = (nd)[1 + d/(α/β)] − (0.693/α)[(T − Tk)/Tpot]
Where n is the number of fractions, d is the fraction
size, a/b ratio is 10 Gy, a is 0.3 Gy, T is the ORT con-
sidering that the first fraction was given on day 1, Tk is
the delay in proliferation in tumors (’kick-off time’ is
assumed to 21 days), Tpot is the potential doubling time
of the tumor clonogenic cells which is set to 3 days for
SCLC [15]. In our study, patients received twice-daily
TRT have intervals longer than 6 h between fractions,
so the impact of incomplete repair to the BED was con-
sidered to be little and was not included in the formula.
Treatment Toxicity
In this study, toxicity associated with TRT was reported
as days of interruption during the course of TRT except
for holidays and mechanical failures. The hematologic
criteria for interruption included absolute neutrophil
count ≤ 1000/mm
3, neutropenic fever or sepsis, and pla-
telet count ≤ 50,000 mm
3. Loco-regional symptoms
included severe esophagitis (i.e., severe dysphagia, intol-
erable pain, requiring IV fluids or tube feedings), and
severe pneumonitis (i.e., severe coughing, dyspnea
requiring oxygen inhalation, need to exclude tumor-
related symptoms).
Follow-up and Statistical Analysis
Generally, patients were followed up every 3-4 months
for 2 years, then every 6 months thereafter. The survival
status of patients lost to follow-up was updated with the
information from the R.P.C Social Security System. OS
was the primary endpoint of this study which was mea-
sured from the start date of any treatment to patients’
death from any cause or the last follow-up. Only the
first treatment failure was taken into account. Progres-
sion-free survival (PFS) was defined as the duration of
survival without loco-regional recurrence or distant
metastases. Local recurrence was defined as disease pro-
gression within the irradiated field alone or together
with distant metastases (diagnosed within one month
after the initial finding of failure), while progression of
tumor out-of-field was not included in this analysis, pro-
vided that this kind of loco-regional recurrence can’tb e
controlled by TRT intensification. Distant-metastases
free survival (DMFS) was defined as the interval from
the day that treatment initiated to the day of distant
metastases occurred or the last follow-up. All endpoints
were estimated by Kaplan-Meier model.
The Duke’s experiences showed that LS-SCLC patients
treated with approximately 60 Gy once-daily TRT have
promising outcomes [4], and this dose is also the lower
limit of 60-70 Gy in conventional fraction recommended
by National Comprehensive Cancer Network (NCCN)
[16]. Therefore, we divided patients into two groups
with a cut-off of BED 57 Gy (equivalent to 60 Gy in 30
fractions over 40 days), with the hypothesis that high
BED is associated with better outcomes. The OS, PFS,
LC and DMFS between the two groups were compared
using the log-rank test. Cox’s proportional hazards
model was used for multivariate analysis to estimate the
simultaneous impact of factors on OS. All p values were
two-sided, with p ≤ 0.05 considered significant.
Results
At the present analysis, 42 patients (20.5%) were alive,
153 dead (74.6%) and 10 censored (4.9%). Median fol-
low-up time was 20.7 months (range 3.6-102.8 months)
for all analyzable patients and 50.8 months (range 27.3-
102.8 months) for patientsa l i v e .C o n s i d e r i n ga l l
patients, median OS was 22.9 months (95% confidence
interval [CI], 20.6-25.2 months); 2- and 5-year OS were
47.2% and 22.3%, respectively.
Of the 205 patients, 70 received BED ≤ 57 Gy (low
BED group) and 135 > 57 Gy (high BED group). Table 1
provided a comparison of patient- and treatment-related
factors between the two groups. No statistically signifi-
cant imbalance was found in these variables except for
the daily fractions. Twice-daily TRT was significantly
more frequent in high BED group (p = 0.000). Addition-
ally, it should be mentioned that we also evaluated the
size of equivalent square field at anterior-posterior axis
as an alternative indicator of tumor volume for each
patient, considered that the prescribed TRT dose may
be affected by the tumor volume. In some cases treated
with three-dimensional conformal TRT, a virtual field
was utilized to generate the size. As a result, there was
no significant difference between the two groups.
The median OS for patients treated with low BED and
those with high BED were 16.4 months (95% CI, 10.9-
21.9 months) and 25.4 months (95%CI, 21.9-29.0
months); 2- and 5-year OS were 31.5% and 14.6%, 55.2%
and 26.2%, respectively (p = 0.005, Figure 1a). The prob-
ability of PFS was significantly higher in high BED group
than in low BED group (p = 0.006, Figure 1b).
The sites of first relapse were recorded for 141 patients
(68.8%). Table 2 listed the patterns of the first failure. In
low and high BED group, local recurrence occurred as
the first failure in 14 and 18 patients, respectively. The
1- and 2-years LC rates were 81.6% and 62.5% in low
BED group, while 90.4% and 83.7% in high BED group,
favouring the high BED group (p = 0.024, Figure 2a). The
most common sites of distant metastasis were brain,
bone, and liver. No statistically significant difference was
found in DMFS between the two groups. However, a
t r e n dt o w a r di m p r o v e dD M F Sw a sn o t e di nt h o s e
patients receiving high BED (p = 0.196, Figure 2b).
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esophagitis. There was no significant difference between
the low and high BED groups in the incidence of Grade 3
esophagitis, defined as an inability to swallow solids,
requiring narcotic analgesics or the use of a feeding tube
(8.6% vs. 10.4%, p = 0.681). Seven patients (3.4%) experi-
enced Grade 3 acute pneumonitis, defined as severe
coughing or dyspnea requiring oxygen inhalation. There
was no difference between the two groups in the incidence
of Grade 3 pneumonitis (2.9% vs. 3.7%, p = 0.752). A total
of 46 patients (22.4%) required treatment interruptions
during TRT due to hematologic and/or loco-regional toxi-
cities. The factors directly leading to treatment interrup-
tions were esophagitis (40.4%), neutropenia (29.8%),
pneumonitis (12.8%), nausea and vomiting, dehydration,
and others (17.0%). The median duration of treatment
“break” was 6 days (range 1-18). Thirteen patients (18.6%)
in low BED group experienced treatment breaks, while 33
(24.4%) in high BED group did. No statistically significant
difference was found in the incidence of interruptions as a
function of BED (p = 0.339).
The effects of patient- and treatment-characteristics
on OS are shown in Table 3. Univariate analysis showed
that age ≤ 65 years, high KPS, weight loss ≤ 5%, high
BED and PCI were significantly associated with
improved OS. BED was also significantly associated with
OS when analyzed as a continuous variable (p =0 . 0 1 9 ) .
T h et i m ef r o mt h es t a r to fa n yt r e a t m e n tt ot h ee n do f
the TRT (SER) was not a significant factor for OS when
SER was analyzed as a continuous variable (p =0 . 5 3 0 )
or as a categorical variable based on the median value
(p = 0.623). There were no significant differences in OS
based on sex, lactate dehydrogenase, ipsilateral supracla-
vicular nodes, daily fraction, TRT technique, chemother-
apy cycles or ORT.
Multivariate analysis demonstrated that age ≤ 65 years,
high KPS, weight loss ≤ 5% and high BED remained sig-
nificantly correlated with improved OS (Table 4), while
PCI was borderline associated with OS (p =0 . 0 5 7 ) .
Figure 3 showed the median OS as a function of BED, a
positive correlation was found although the slope of the
BED-response seems relatively flat in the low BED
region (p = 0.012).
Discussion
This retrospective study showed that patients treated
with BED > 57 Gy had significantly better LC, PFS and
OS in LS-SCLC, indicating that patients could achieve
benefits from high BED. This result is consistent with
previous findings that TRT dose intensification improved
LC, resulting in better outcomes in LS-SCLC [3,5,17].
Table 1 Patient and treatment characteristics
Characteristic Lower BED Group
(≤57 Gy)
Higher BED Group
(>57 Gy)
P
Patients(n) 70 135
Age(years)
Median 62 60 0.574
Range 38-83 35-81
Gender 0.713
Male 57(81.4)* 107(79.3)
Female 13(18.6) 28(20.7)
KPS
Median 80 80 0.163
Range 60-100 60-100
Weight loss>5% 0.178
Yes 21(30.0) 29(21.5)
No 49(70.0) 106(78.5)
LDH 0.517
≤220 IU/L 35(43.1) 34(35.3)
>220 IU/L 25(26.4) 78(22.6)
Unknown 10(30.5) 23(42.1)
ISN 0.190
Yes 8(11.4) 25(18.5)
No 62(88.6) 110(81.5)
CHT cycles 0.620
Median 4 6
Range 3-8 3-7
SER 0.951
Median 81 72
Range 34-262 30-236
BED(Gy) 0.000
Median 53.6 58.5
Range 41.3-56.9 57.1-66.1
TRT fractions 0.000
Once-daily 52(74.3) 23(17.0)
Twice-daily 18(25.7) 112(83.0)
TRT technique 0.418
2D 52(74.3) 107(79.3)
3D 18(25.7) 28(20.7)
Size of TRT field
(cm
3)
#
0.722
Median 132 137
Range 54-210 46-228
PCI 0.199
Yes 11(15.7) 13(9.6)
No 59(84.3) 122(90.4)
* Data in parentheses are percentages.
# The size of equivalent square field at anterior-posterior axis
Abbreviations: BED = biologically effective dose with time correction; KPS =
Karnofsky performance score; LDH = lactate dehydrogenase; ISN = ipsilateral
supraclavicular nodes; CHT = chemotherapy; SER = the time from the start of
any treatment to the end of chest irradiation; TRT = thoracic radiation
therapy; 2D = 2 dimension; 3D = 3 dimension; PCI = prophylactic cranial
irradiation.
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50 Gy, which is high compared to doses adopted by pre-
vious studies [10-12]. Our results supported the hypoth-
esis that a biologically dose-response relationship still
existed even in a relatively high radiation dose range for
LS-SCLC.
The radiation dose ≥ 50 Gy determined as the inclu-
sion criteria for this retrospective analysis was based on
our assumption that 50 Gy might be a conservative
radiation dose for our LS-SCLC population with cura-
tive intent when sequential chemoradiotherapy was
given, according to our previous study [13]. In the cur-
rent analysis with a large sample size, patients who
received BED > 57 Gy had significantly better LC rate,
with a trend toward better DMFS. It was suggestive that
further improving LC of the primary tumor with high
BED may play a major role in reducing the risk of sub-
sequent metastasis and that combination of improved
LC and decreased distant metastasis would finally con-
tribute to better OS in patients treated with high BED.
In addition, our results showed that high BED was sig-
nificantly associated with improved OS in patients with
LS-SCLC, which is comparable to the findings of Schild
et al., of which a strong positive correlation between
BED and 5-year OS was shown with a reported Pearson
correlation coefficient of 0.81 based on randomized
trials that included various TRT programs for LS-SCLC
[18]. Results from these studies suggested that for LS-
SCLC, high BED which integrated the factors of TRT
dose and ORT is important to achieve a better outcome.
Accelerated proliferation of tumor clonogens during
radiotherapy has been shown to affect outcomes in
many malignant solid tumors [19-22]. Two studies
aimed to evaluate the impact of ORT on the results of
TRT for non-small cell lung cancer showed that pro-
longed ORT accompanied with accelerated proliferation,
was a major cause of treatment failure, which provided
evidence that dose and time factors should be consid-
ered together for a reliable evaluation of a radiotherapy
regimen [21,22]. Although the evidence for SCLC is not
as strong for other solid tumors, it is believed that accel-
erated proliferation during TRT also exist in SCLC due
to its characteristics of rapid doubling time and high
growth fraction. Also, several studies explored the
Figure 1 Curves for overall survival (a) and progression-free survival (b). Comparison between biologically effective dose (BED) > 57 Gy
and BED ≤ 57 Gy groups for patients with limited-stage small-cell lung cancer, both favouring the BED > 57G group.
Table 2 Patterns of first treatment failure
Treatment No. of Patients Distant Metastases Alone Local-regional Recurrence Censored Observations
Alone or with Distant Metastases Alone
Lower BED group(≤57Gy) 70 28(40)
b 21(30) 17(24) 21(30)
Higher BED group(>57 Gy) 135 60(44) 32(24) 20(15) 43(32)
All patients 205 88(43) 53(26) 37(18) 64(31)
Censored observations indicate patients without recurrences or loss of follow-up.
Data presented as the number of patients, with the percentage in parentheses.
Abbreviations: BED = biologically effective dose with time correction.
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extended ORT had a potential negative effect in the
treatment of LS-SCLC [23-25]. Therefore, we think that
it is more appropriate to include ORT for the examina-
tion of the relationship between BED and treatment out-
comes in our analysis.
Indeed the biological radiation dose (without time cor-
rection) in the high once-daily [6,7] or the concomitant
b o o s tT R T[ 8 , 9 ]i sh i g h e rc o m p a r e dt ot h a tu s e di nt h e
Intergroup Trial 0096 [3], but at the expense of pro-
longed ORT which could potentially lead to repopula-
tion. This should be considered as one of the reasons
for the less satisfying results in the several phase II
clinical trials exploring high radiation dose [6-9], and 45
Gy twice-daily TRT should be considered as the stan-
dard treatment in LS-SCLC at this time. Currently, two
ongoing randomized Phase III trials (CONVERT and
CALGB 30610/RTOG 0538) are investigating the opti-
mal dose of radiation in LS-SCLC [26,27]. The former
uses a conventional regimen of 66 Gy in 33 treatments
given daily as the experiment arm, and the latter
includes two experiment arms: 70 Gy in 35 treatments
given daily and 61.2 Gy in 34 treatments given daily, 5
days/week for 16 days, and then twice-daily, 5 days a
week for 9 days. Both trials are using the 45 Gy twice-
daily dose as the control arm, which will provide more
data on the repopulation issue in LS-SCLC.
The distributions of patient- and treatment-related
characteristics were similar for low and high BED
groups except for daily fraction scheme. Twice-daily
scheme was more frequent in high BED group than in
low BED group (83% vs. 26%, p =0 . 0 0 0 ) .H o w e v e r ,
there was no significant difference in 5-years OS
between the once-daily and twice-daily groups, (21.5%
Figure 2 Curves for local tumor control and distant-metastasis-free survival. Comparison between biologically effective dose (BED) > 57 Gy
and BED ≤ 57 Gy groups for patients with limited-stage small-cell lung cancer. (a) Patients in BED > 57 Gy group had significantly better local
tumor control. (b) A trend toward better distant-metastasis-free survival was also found for the BED > 57 Gy group.
Table 3 Univariate Cox regression analysis for overall
survival
Factor Hazard ratio p 95% CI
Age (>65 y vs. ≤65 y) 1.667 0.007 1.147-2.424
Gender (female vs. male) 0.625 0.062 0.381-1.023
KPS (>80 vs. ≤80) 0.496 0.005 0.304-0.810
Weight loss (>5% vs. ≤5%) 1.820 0.004 1.205-2.749
LDH(>220 IU/L vs. ≤220 IU/L) 1.226 0.328 0.815-1.843
ISN (pre-treatment, yes vs. no) 1.408 0.166 0.867-2.287
Daily Fractions (once vs. twice) 1.112 0.575 0.768-1.609
TRT technique (3D vs. 2D) 0.821 0.357 0.539-1.249
CHT cycles (>5 vs. ≤5) 0.721 0.126 0.475-1.096
SER (>79 vs. ≤79 day) 1.097 0.623 0.758-1.587
ORT (>31 vs. ≤31 day) 1.356 0.106 0.937-1.964
BED (>57 vs. ≤57 Gy) 0.600 0.005 0.414-0.870
PCI (yes vs. no) 0.506 0.018 0.288-0.888
Abbreviations as in Table 1.
Table 4 Multivariate Cox regression analysis for overall
survival
Factor Hazard ratio p 95% CI
Age (>65 y vs. ≤65 y) 1.776 0.003 1.209-2.609
KPS (>80 vs. ≤80) 0.487 0.009 0.284-0.835
Weight loss (>5% vs. ≤5%) 1.693 0.023 1.076-2.665
BED (>57 vs. ≤57 Gy) 0.574 0.004 0.395-0.836
PCI (yes vs. no) 0.575 0.057 0.325-1.016
Abbreviations as in Table 1.
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administered in once-daily scheme might lead to non-
inferior outcomes compared with twice-daily scheme for
LS-SCLC. Therefore, we believed that the difference of
daily fraction scheme between the two groups had no
apparent impact on our conclusions.
The differences between the physical constitution and
patient compliance of the Asian and Western population
may have resulted in different management of the LS-
SCLC patients here in China. The Turrisi et al. schedule
[3] had been tried in our centre, but unsuccessful predo-
minantly because of severe esophagitis and bone mar-
row suppression occurred as a side effect in a large
percentage of patients [13]. In the past, there was no
sufficient nutrition support and granulocyte colony-sti-
mulating factor supply, and sequential treatment of LS-
SCLC was a more favourable treatment option in china,
which was also common in other developing countries
[28]. During the period, most physicians in our centre
chose late commencement of TRT due to expected
smaller treatment fields after initial shrinkage of the
tumor mass occurring after induction chemotherapy. As
more evidence supporting early administration of TRT
emerging in recent years [29,30], more and more
patients received early TRT in our centre.
The median OS were 22.9 months and 5-year OS was
22.3% in this study, which was within the range of other
reports using early concurrent chemoradiotherapy
[3,23]. The results were acceptable, although concurrent
chemoradiothrapy was not used in this population and
most of the patients were administered with TRT late.
This might be explained by the facts that: 1) only those
patients who completed induction chemotherapy and
TRT doses ≥ 50 Gy were included in this analysis, this
criteria might excluded some patients with poor prog-
nosis and those who had poor compliance to treatment;
2) all the patients in this study received high dose TRT,
to some extent, contributed to the improvement of the
treatment outcomes.
Because it was difficult to accurately evaluate treat-
ment toxicities in this retrospective study, interruption
during TRT was used as an alternative indicator. The
interruption occurred in 22.4% of the patients even
when TRT was delivered with relatively high dose,
which was similar to previous report [31]. The possible
explanation for lower incidence of acute toxicity was
that we used a modified schedule of chemoradiotherapy
and TRT with involved-field irradiation technique for
LS-SCLC, both of which were considered to possibly
reduce the incidence of treatment toxicities. Nowadays,
there have been many advances which contributed to
making TRT dose intensification feasible, including ima-
ging techniques, radiation planning and radiation deliv-
ery. Furthermore, there is a trend towards smaller fields
with the omission of elective nodal irradiation [32],
which will further help TRT intensification by limiting
dose-dependently aggravated toxicity in radiotherapy.
Nevertheless, the available data about treatment asso-
ciated toxicities for LS-SCLC were generally based on
old irradiation techniques with a large portal, which to a
certain extent, limited the possible benefits from intensi-
fied TRT. Future studies should examine the beneficial
and detrimental effects of high BED with modern irra-
diation techniques and an appropriate TRT portal.
This study had some limitations. Because only the site
of first failure was recorded, data on local recurrence
after distant metastasis were censored. Thus, it had the
risk of obscuring the true LC rate. The issue of LC was
further complicated by the difficulty in defining local
failure. It was very hard to evaluate local failure accu-
rately because of limited ability of imaging modality to
discriminate the radiographic abnormality, which was
also the reason for choosing OS as the primary end
point in our study. We believed that OS could be more
appropriate to evaluate the impact of TRT intensifica-
tion on treatment outcomes than LC [33]. In addition,
uncontrolled chemotherapy dose in this population
could be another potential confounder. It is well known
that chemotherapy is the corner stone for the manage-
ment of SCLC, thus insufficient chemotherapy dose may
offset the possible benefits from escalation of BED, lead-
ing to compromised treatment outcomes. In this study
the relatively high incidence of distant metastasis might
be due to inadequate chemotherapy intensity. Therefore,
it was believed that the benefits from escalation of BED
would become more prominent when sufficient che-
motherapy dose intensity was given in a prospective
study. Lastly, the majority of patients in our report
received modified chemoradiotherapy rather than a
standard regimen of concurrent chemoradiotherapy,
which seemed to be a possible confounder. While this
Figure 3 Median survival as a function of biologically effective
dose for limited-stage small-cell lung cancer.
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Page 7 of 9work is intended to investigate the relationship between
radiation dose and treatment outcomes, we considered
that the factor of timing and sequencing of TRT has lit-
tle influence to our conclusion about radiation dose-
response because of the consistent chemotherapy
administration in this population.
Conclusions
In summary, our study showed that patients with BED >
57 Gy had significantly better LC, PFS and OS than
those with BED ≤ 57 Gy in LS-SCLC population treated
with TRT physical dose ≥ 50 Gy, indicating that a biolo-
gically dose-response relationship still existed even in a
relatively high radiation dose range for LS-SCLC. How-
ever, the data on toxicities for LS-SCLC treated with
high BED is still limited, especially with modern irradia-
tion technique. A prospective phase I/II study of accel-
erated three-dimensional conformal hypofractionated
TRT with 55 Gy in 22 fractions over 30 days (BED 62
Gy) plus concurrent chemotherapy in patients with LS-
SCLC is ongoing in our centre, with the hypothesis that
both high TRT dose and short ORT are important for
the treatment of LS-SCLC.
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